Patent intelligence · US
US 11471448
Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
Patent details — US 11471448
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 18, 2022
- Expiration
- Oct 13, 2042
- Applicant
- RedHill Biopharma Ltd.
- Claims
- 20
- CPC classes
- A61K, A61K31/4409, A61K9/48, A61P
Quick answer
US 11471448 (Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia) is held by RedHill Biopharma Ltd.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RedHill Biopharma Ltd.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/4409, A61K9/48, A61P, A61P31/14
More from RedHill Biopharma Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12370206
Therapy for inhibition of single-stranded RNA virus replication
granted -
US 12115150
Biomarkers of coronavirus pneumonia
granted -
US 11931463
All-in-one fixed-dose combination for treating Helicobacter pylori infection
granted -
US 11918560
Serine protease inhibitor for treating coronavirus infection
granted -
US 11878011
Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
granted -
US 11786541
Inhibitor of sphingosine kinase 2 for treating Ebola
granted -
US 11633385
Combination compositions for treatment of cancer
granted -
US 11590154
Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
granted
Frequently asked questions
What is US patent 11471448?
US 11471448 (Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia) is held by RedHill Biopharma Ltd.. Status: granted. Granted Oct 18, 2022. Expires Oct 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11471448?
RedHill Biopharma Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11471448 expire?
Our index shows an expiration date of Oct 13, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.